Episode 163 - November 14, 2025

What It Covers

Biotech industry leaders analyze FDA leadership changes with Rick Pazdur's CDER appointment, debate the new plausible mechanism pathway for rare disease therapies, examine major M&A activity including Pfizer-MedSera and Merck-Cidara deals totaling over $20 billion, and review clinical data from Alkermes' narcolepsy program and CRISPR's ANGPTL3 gene editing trial.

Key Questions Answered

• •FDA Stability Under Pazdur: Rick Pazdur's appointment as CDER director after 25+ years at FDA brings regulatory stability following George Tidmarsh's departure. His oncology expertise and collaborative photo with Marty Makary and Vinay Prasad signals potential for consistent drug approval processes, though industry remains cautious about maintaining this stability long-term given recent regulatory inconsistencies between stated policies and actual enforcement actions.
• •Plausible Mechanism Pathway Details: FDA's new pathway allows single-patient data to support marketing approval for gene therapies targeting biologically defined mutations with measurable clinical outcomes. Patients serve as their own natural history controls, with platform technology potentially supporting multiple indications. Implementation remains unclear regarding how few patients constitute sufficient evidence and whether this applies to programs like Unicure's Huntington's therapy currently facing FDA challenges.
• •Competitive M&A Dynamics: Lundbeck's $2.6 billion counter-offer for Avadel versus Alkermes' $2.1 billion bid represents second recent competitive acquisition scenario. Lundbeck structures $2 CVR tied to 2027 and 2030 sales milestones versus Alkermes' $1.50 CVR linked to idiopathic hypersomnia approval. FTC antitrust concerns may differ between bidders despite both companies targeting sleep disorders with different mechanisms and scheduling classifications.
• •Orexin Agonist Data Comparison: Alkermes' VIBRANCE-2 trial in 93 narcolepsy type 2 patients showed 9.3, 6.7, and 6.7 minute placebo-adjusted improvements in maintenance of wakefulness test at week 6 for three doses. Larger sample size and longer duration versus Syntessa's 10-patient, week-2 data provides more reliable efficacy assessment. ESS scores improved to normal range (10 points) at higher doses with lower visual disturbance rates enabling potential dose escalation strategies.
• •CRISPR Gene Editing Safety Concerns: CRISPR's ANGPTL3 Cas9 therapy achieved 73% protein reduction and 55% triglyceride reduction in 15 patients with mixed dyslipidemia, but one death occurred (deemed unrelated). Intellia's ATTR cardiomyopathy program faces clinical hold after elderly patient death from grade 4 transaminitis in phase 3 trial dosing 650+ patients. New England Journal calls for 15-year surveillance of in vivo genome editing raising questions about risk-benefit versus established therapies.